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the characteristics of community pharmacies in Egypt. The current study and 
future ones would significantly improve the ability to probe practice-related 
issues and economic challenges community pharmacies and pharmacists face in 
Egypt.  
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OBJECTIVES: HTA agencies are mushrooming in Europe. Industry faces the 
challenge to meet their diverse requirements and comply with decision criteria. 
Our aim was to investigate similarities and distinguishing characteristics of HTA 
agencies, to identify the anchor institutes that use different approaches to HTA 
and serve as a reference for others, and to assign other countries to one of the 
anchor institutes. METHODS: We identified the primary institutions in European 
countries where HTA plays a role in decision making. We developed a template 
for the unified assessment of the input needs of the agencies, and a set of 
criteria an anchor country should meet.. Agencies were assessed based on a 
literature review, and assigned to one of the anchor countries, which was 
validated by MSD subsidiaries across Europe. Future trends in anchor countries 
were investigated. RESULTS: We identified three anchor institutes in Europe 
using different value assessment concepts. IQWIG in Germany primarily 
assesses HTA submissions on the basis of patient related outcomes requiring 
hard endpoints. HAS in France sees the medical benefit of technologies in 
innovativeness rating them from no innovation to breakthrough innovation. 
NICE in England asks for evidence of cost-effectiveness as one of its major 
considerations. We found that other European countries tend to primarily follow 
one of these concepts. Analysing future trends, one can see converges in the 
fields of HTA requirements, between regulatory and HTA, in coordination and 
process harmonization, and regional and international collaboration. 
CONCLUSIONS: European HTA agencies can be systemized based on their 
requirements. This review can serve as a depository of individual country needs 
in HTA, an input to the design of clinical trials, and can support the development 
of industrial HTA strategies. Such a snapshot however cannot substitute the 
deep knowledge of local requirements and needs regular update to follow-up 
future trends.  
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OBJECTIVES: A pilot care managing programme was introduced in Hungary in 
1999. The conceptual foundations of the Hungarian implementation of managed 
care is closer to what was called the GP fundholding in the UK than HMOs in the 
USA. The purpose of the study is to analyse the changes in the number of 
enrolees in the care managing programme. METHODS: The data derive from the 
financial database of the Hungarian National Health Insurance Fund 
Administration (NHIFA) covering the period 1999-2007. We identified the average 
annual number of persons enrolled to Care Managing Organizations. The 
Hungarian CMOs was financed through a risk adjusted capitation fee and the 
health services covered by CMOs were defined in legal regulations. RESULTS: 
The total number of the Hungarian population was around 10 million people  
(100 %) during the study period. Since the beginning of the programme (1999) the 
total number of persons covered by the care managing programme increased 
from 158,984 (1.5 % of the Hungarian population) to 601,915 persons (5.9 %)  
in 2003 and to 1,961,025 (19.4 %) in 2005. After this peak, the number of enrolees 
decreased to 1,823,732 persons in 2006 and 1,409,475 persons in 2007. Later  
the Hungarian managed care pilot programme was cancelled. CONCLUSIONS: 
With the development of the Hungarian care managing system, the  
average number of enrolees increased. This increase resulted in larger risk-
pooling structure providing a more stable environment for Care Managing 
Organizations.  
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OBJECTIVES: To determine the types of approaches preferred by payers to 
enhance the P&T decision-making process and how medications accepted onto 
the formulary should be covered. METHODS: An online-interactive survey of US 
medical/pharmacy directors (MDs+PDs, respectively). In addition to a 10-point 
Likert scale (10=agree completely, 1=disagree completely), some questions used 
qualitative responses and interpretive analysis to explore views and beliefs. 
RESULTS: Twenty-nine (20 MDs+9 PDs) responded, representing 44 commercial 
plans,19 Medicaid plans, and 23 Medicare plans. Respondents indicated that 
current progress in obtaining usable comparative-effectiveness research (CER) 
information was slow (average=4.17; MD=4.06; PD=4.40 on the 10-point scale). 
However, they anticipate regularly utilizing CER information in formulary 
decision making by 2015 (average=6.03; MD=6.0, PD=6.1). Their rating of the use 
of evidence-based medicine in coverage decision making today was somewhat 
higher (average, 7.08; MD=7.38, PD=6.40). The survey participants pointed out 
that emerging CER results will greatly affect the following areas: 
Optimization/improvement of clinical guidelines (22.6%), medical/pharmacy 
benefit management (19.4%), evaluation of the value (16.1%), appropriateness of 
care (16.1%), pharmaceutical R&D (6.5%). When asked how they would change 
their plan/PBM’s pharmacy benefit design, the most frequent responses  
were incorporating CER data into copayment tiering management (13.3%), 
further incentivizing adherence through benefit design (10.0%), and altering 
benefit design structures for specialty pharmaceuticals (10.0%), primarily 
lowering member out-of-pocket costs. To improve their P&T Committee process, 
23.3% would incorporate more CER results, 13.3% would enhance the 
physician/specialist presence on the review committee, and 6.6% would increase 
the time allowed for review to allow for a more in-depth evaluation. 
CONCLUSIONS: The environment for P&T Committee decision making  
in managed care is undergoing a series of changes, and payer medical directors 
and pharmacy directors, who commonly serve as P&T Committee  
members, have distinct opinions as to how to alter the process to adapt to these 
influences.  
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OBJECTIVES: Patient Access Schemes (PASs) are part of the UK Pharmaceutical 
Price Regulation Scheme (2009). PASs enable patients to receive drugs, and allow 
pharmaceutical companies to collect cost-effectiveness and efficacy data, even if 
the payer classified the drug as outside the cost-effectiveness threshold. This 
project analysed the effect of PASs on patient access (PA) (defined by total sales 
in volume/prevalence of the particular disease group). METHODS: A literature 
search of Medline and online resources was carried out to capture relevant data 
on PASs, however no suitable publications on the relationship between PA and 
PASs were obtained. Multiple regression was used to test if a relationship exists 
between the dependent variable, (change in PA) and the independent variable 
(existence of a PAS) and other factors that may affect change in PA. The other 
factors were: type of PAS, country, number of competitors, list price, how long 
the drug has been marketed for, and the orphan drug designation. Five drugs 
with approved PASs in the UK were analysed. These included: lenalidomide, 
erlotinib, bortezomib, sunitinib, and cetuximab. These were analysed in France, 
Germany, Italy, Spain and the UK, between 2010 and 2011 using IMS sales data 
and the Globocan Project 2008 prevalence data. RESULTS: The results of the 
regression analysis showed the existence of a PAS does not seem to have an 
effect on the change in PA. Therefore, this model cannot support a relationship 
between these two variables. The R2 is 0.6119, however the only variable which 
was statistically different from 0 is the number of competitors, with a p-value of 
0.014; which means it is the only variable which had a significant effect on the 
change in PA. CONCLUSIONS: Further research needs to be conducted for a 
detailed analysis on this relationship.  
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OBJECTIVES: The Centers for Medicare and Medicaid Services (CMS) makes 10-12 
National Coverage Determinations (NCDs) for medical interventions each year. 
Our objective was to identify evolving trends in NCDs. METHODS: We analyzed 
data from the Tufts Medical Center NCD database, which contains detailed 
information on 165 NCDs since 1999. We evaluated trends in how CMS reported 
evidence limitations, the use of its “coverage with evidence development” (CED) 
policy, the type of intervention evaluated, and whether it was for prevention or 
treatment. We used two-sided Armitage-Cochrane (CA) tests to identify 
statistical annual trends. RESULTS: Over time, CMS has increasingly cited 
evidence limitations in decision memoranda. The proportion of occasions CMS 
cited a “lack of relevant health outcomes” increased from 14% in 2000 to 67% in 2012 
(p<0.0001; CA test, 1999-2012). The proportion of occasions CMS cited, a “lack of 
studies including Medicare beneficiaries” increased from 7% in 2000 to 67% in 2012 
(p=0.0003; 1999-2012). CMS has increasingly relied on coverage with evidence 
development (CED) policies (p=0.0292; 2003-2012). Since 2009, 10 NCDs (29% of 
NCDs in this period) resulted in CED policies, more than half of all CEDs (n=19) 
implemented since 2003. In recent years, NCDs have increasingly pertained to 
primary and secondary prevention level interventions (p=0.0971; 1999-2012), and 
now represent 28% (46/165) of all NCDs. The type of intervention evaluated also 
changed, with more NCDs pertaining to “diagnostic imaging technology” 
(p=0.0971; 1999-2012), now representing 15% (25/165) of all NCDs, and “health 
education and behavior” (p=0.0195; 1999-2012), now representing 7% (11/165) of 
all NCDs. CONCLUSIONS: CMS’s NCD process is evolving in important ways. CMS 
increasingly notes that technologies considered lack relevant outcomes. The 
agency increasingly uses CED policies to grant narrow access to medical 
technology, while collecting evidence for future use. It increasingly uses NCDs to 
evaluate preventive services and diagnostic technologies.  
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